.25mg of semaglutide Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) This medication is used with a doctor Ozempic (Semaglutide Injection) 0.25mg or

GIP and GLP-1 Receptor Activation in the Gut Itself GIP and GLP-1 receptors aren't just in the brain and pancreas they're scattered through the small and large intestine, where they directly influence gut motility and fluid secretion

5-Amino-1MQ Research Overview Acting on metabolic pathways, 5-Amino-1MQ is widely examined for its influence on fat storage and energy utilization

Lancet Diabetes Endocrinol 7(10):776785 Muskiet MHA, Smits MM, Morsink LM, Diamant M (2014) The gutrenal axis: do incretin-based agents confer renoprotection in diabetes

Epigenetic mechanisms in memory formation

Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications